# 2026-04888: FDA Speeds Up Eye Drug for Rare Kids' Disease with Magic Voucher

2026-04888, Notice of Approval of Product Under Voucher: Rare Pediatric Disease Priority Review Voucher; EYLEA HD (aflibercept), is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2026-03-13, effective 2025-11-19; PRIA reads it as touching household money (as of 2026-06-08).

- Canonical: https://policyrisk.com/federal-register/2026-04888
- As of: 2026-06-08
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-04888
- Title: Notice of Approval of Product Under Voucher: Rare Pediatric Disease Priority Review Voucher; EYLEA HD (aflibercept)
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 91 FR 12421
- Published: 2026-03-13
- Effective: 2025-11-19
- Comments close: not stated
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-06-08

## In one line

FDA Speeds Up Eye Drug for Rare Kids' Disease with Magic Voucher

## Summary

The FDA just approved EYLEA HD (aflibercept) using a special Rare Pediatric Disease Priority Review Voucher, speeding up its review because it treats a rare childhood illness. This means the company behind EYLEA HD got a fast-track pass, helping kids get medicine sooner. Keep an eye out for more rare disease treatments moving faster thanks to this program!

## Abstract

The Food and Drug Administration (FDA) is announcing the issuance of approval of a product redeeming a priority review voucher. The Federal Food, Drug, and Cosmetic Act (FD&C Act) authorizes FDA to award priority review vouchers to sponsors of approved rare pediatric disease product applications that meet certain criteria. FDA is required to publish notice of the issuance of priority review vouchers as well as the approval of products redeeming a priority review voucher. FDA has determined that the supplemental application (Supplement-10) for EYLEA HD (aflibercept), approved November 19, 2025, meets the criteria for redeeming a priority review voucher.

## Effects PRIA read

- Faster Approval for Rare Pediatric Drug: benefit, high. If you have a child with the rare pediatric condition treated by EYLEA HD, the FDA approved EYLEA HD (aflibercept) using a Rare Pediatric Disease Priority Review Voucher. The supplemental application was approved on November 19, 2025, and the voucher sped up the review so children can access the me…

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2026-04888 on federalregister.gov](https://www.federalregister.gov/documents/2026/03/13/2026-04888/notice-of-approval-of-product-under-voucher-rare-pediatric-disease-priority-review-voucher-eylea-hd)
- [2026-04888 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-03-13/pdf/2026-04888.pdf)

## Related
- [Previous: 2026-04887, Flixbus SE, Flix North America Inc., and Greyhound Lines, Inc.-Control-Pacific…](https://policyrisk.com/federal-register/2026-04887)
- [Next: 2026-04891, Agency Information Collection Activities; Submission for OMB Review; Comment Re…](https://policyrisk.com/federal-register/2026-04891)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-04888 (as of 2026-06-08).
